The invention relates to an application of a pharmaceutical composition in inhibition of ras proto-
oncogene overexpression, and specifically, relates to the application in preparation of anti-tumor drugs for inhibiting ras proto-
oncogene overexpression. Specifically, the pharmaceutical composition contains radix
ginseng,
radix ophiopogonis and
schisandra chinensis fruits. Researches indicate that about 90% of
pancreatic cancer, 50% of colon
cancer, 30%-40% of
lung adenocarcinoma and 5%-40% of
leukemia are caused by the ras proto-
oncogene overexpression, and a Ras
protein becomes a universally accepted target for screening related malignant tumor drugs. Animal experiments indicate that the pharmaceutical composition can specifically down-regulate overexpression caused after ras proto-oncogene
mutation, but does not act on wild-type ras proto-oncogenes, so that the pharmaceutical composition is low in
toxicity and has no teratogenic effect and no
reproduction toxicity; the pharmaceutical composition can be used for preparation of drugs for tumors caused by overexpression after ras proto-oncogene
mutation, can be mixed with any one of pharmaceutically acceptable auxiliary materials to prepare various dosage forms, and is expected to be developed into a new-generation antitumor drugs.